The Glucagon-Like Peptide 1 (GLP-1) Agonist market is currently undergoing a historic transformation. What was once a niche class of drugs for blood sugar control has evolved into a global pharmacological phenomenon, primarily driven by the "Weight Loss Revolution" and the broadening of therapeutic indications to include cardiovascular and renal health. Market Overview GLP-1 agonists...